DR alpha chain ; HLA class II histocompatibility antigen ; HLA class II histocompatibility antigen DR alpha chain ; HLA DRA ; HLA DRA1 ; HLA-DRA ; HLADRA1 ; Major histocompatibility complex class II DR alpha ; MHC cell surface glycoprotein ; MHC class II antigen DRA
Categories
Primary Antibodies
Cellular Localization
Cell Surface
Chromosome Location
6p21.3
Clonality
Monoclonal
Description
This antibody detects a monomorphic general framework determinant of HLA-DR Class II antigen. It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense cytoplasmic staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts.
Host
Mouse
Immunogen
Human peripheral blood leukocytes
Isotype
IgG2b Kappa
Positive Control
Ramos, Daudi or HuT78 cells. Tonsil or lymph node
Reactivity
Human, Cow, Cat
Recombinant
FALSE
Regulatory
RUO
Swissprot
P01903
Uniprot
520048
Gene Id
3122
Buffer
200μg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA; 0.05% azide. Also available WITHOUT BSA; azide at 1.0mg/ml.
Concentration
1.0mg/ml
Description
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Purity
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Applications
FACS, IF
Description
Optimal dilution for a specific application should be determined., FACS ; IF
Dilution
FACS
0.5-1μg/million cells in 0.1ml
IF
0.5-1μg/ml
Reviews of Anti-HLA-DRA (MHC II) Antibody BHA10201853